Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Skip to article
Collection contents

Lupus nephritis · For patients · Chapter 7

The medicines: different drugs, different jobs

A practical map of lupus nephritis medicines, from hydroxychloroquine and mycophenolate to targeted treatments and kidney protection.

Open access
On this page

Seeing a medicine described elsewhere as a transplant drug or cancer treatment can be unsettling. Medicines often have more than one use. In lupus nephritis, the reason for prescribing them is the immune process or kidney problem they can address. The name of another disease on the leaflet does not mean you have that disease, and the regimen may be different.

This is a map of roles, not a menu from which to assemble a combination. The best choice depends on the kidney findings, other illnesses, previous treatment, safety and access.

The foundation and early inflammation control

Hydroxychloroquine helps control lupus over time and is generally recommended in lupus nephritis unless contraindicated. It usually remains part of the plan alongside kidney-directed treatment; it is not sufficient by itself for most active proliferative nephritis. Dose selection and retinal monitoring matter, particularly when kidney function is reduced.

Glucocorticoids, such as prednisone or intravenous methylprednisolone, can suppress inflammation relatively quickly. They may be used more intensively at the start, followed by a planned reduction. Sleep, mood, glucose, blood pressure, bone and infection effects are among the reasons to limit exposure while maintaining disease control. An agreed taper is different from abruptly stopping.

Medicines that control immune cell activity

Mycophenolate is commonly used in initial and longer-term treatment. Mycophenolate mofetil and enteric-coated mycophenolate sodium provide related treatment, but their tablet strengths are not interchangeable milligram for milligram. Gastrointestinal symptoms, blood counts and infection risk require attention. It can cause pregnancy loss and birth defects, so reproductive planning belongs in the discussion before treatment, not after a positive test.

Cyclophosphamide is an option for controlling active nephritis, commonly given intravenously in a defined course. Monitoring includes blood counts, infection and bladder risks. Effects on fertility and cumulative exposure deserve discussion before treatment whenever circumstances allow. Its use does not imply a cancer diagnosis.

Azathioprine may be used for longer-term treatment in selected circumstances, including when another medicine is unsuitable or reproductive plans affect the choice. It still needs blood and liver monitoring and an interaction review. “An alternative” does not mean that it can replace any other medicine without a new plan.

Targeted and combination treatments

Belimumab reduces signaling through a B-cell survival pathway called BAFF/BLyS. It is used with background therapy rather than as a substitute for the whole regimen. In the United States, it is approved for active lupus nephritis from age five; route and schedule depend on the product and patient. Infection, allergic reactions and mood symptoms are part of the safety discussion.

Calcineurin inhibitors include voclosporin, tacrolimus and cyclosporine. They affect immune activity and can also reduce protein leakage through effects on the kidney filter. A rapid fall in protein therefore does not, on its own, prove that every inflammatory change has disappeared. Kidney function, blood pressure and drug interactions need close monitoring. Voclosporin has a specific US adult lupus nephritis indication with background treatment; the drugs are not automatically interchangeable.

Obinutuzumab targets CD20-bearing B cells and is now a US-approved option for adults with active lupus nephritis receiving standard therapy. It is given by infusion. Hepatitis B screening and monitoring for infusion reactions, infections and changes in blood counts are important. Its evidence and approved role differ from those of rituximab, another anti-CD20 medicine sometimes used off-label in difficult-to-treat nephritis. Sharing a target does not make two drugs equivalent.

Medicines that protect the kidney in other ways

An ACE inhibitor or angiotensin receptor blocker may be prescribed to reduce protein loss and manage blood pressure. That purpose can matter even when you do not think of yourself as having hypertension. These medicines require attention to potassium, kidney function and pregnancy considerations. Diuretics can help manage excess fluid; they do not treat the underlying lupus inflammation.

Other prescriptions may address infection prevention or bone protection according to the regimen and your risks. Not everyone needs every preventive medicine. The safety chapter explains how monitoring and prevention fit into treatment.

Keep one coordinated medication list

  • Record the exact product, dose and purpose, including non-prescription medicines and supplements.
  • Ask what to do if you miss a dose, vomit or develop an infection; instructions differ between medicines.
  • Check who authorizes changes when several specialists are involved.
  • Ask which reproductive and vaccination discussions should happen before the next dose.

Some well-established lupus nephritis uses are off-label, while others have a specific regulatory approval. These terms describe licensing, not a simple ranking of “good” and “bad” treatment. Availability and labels differ between countries; the individual plan should make the reason for each choice clear.

Names you may see in a US pharmacy

Examples include hydroxychloroquine (Plaquenil), mycophenolate mofetil (CellCept), mycophenolate sodium (Myfortic), belimumab (Benlysta), voclosporin (Lupkynis), and obinutuzumab (Gazyva). A brand name does not change the need to check the ingredient, formulation and dose. These products have different roles and approval status; they are not interchangeable.

ACE inhibitors and ARBs can harm a developing baby. Pregnancy plans or a positive pregnancy test require prompt review with the prescriber so that kidney and blood-pressure treatment can be changed safely.

Sources and further reading

Back to collectionBack to EssentialsFor professionals · English

Rheumatology in Perspective · by Olga Goodman, MD
A RheumaView publication

Evidence checked: 17 October 2026

Educational information. Individual decisions belong with the treating clinical team.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: lupus nephritis